Market Overview

UPDATE: Bank of America Raises PO to $173 on Biogen Idec on Strong Hemophilia Data

Share:
Related BIIB
Is More M&A On The Way For Large-Cap Biotechs?
With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI
Earnings Season: The Good, The Bad, And The Ugly. And Why I Remain A Bull (Seeking Alpha)

Bank of America reiterated its Buy rating on Biogen Idec (NASDAQ: BIIB) and raised its price objective from $157 to $173.

Bank of America said, "BIIB and partner SOBI reported positive and better-than-expected Phase 3 results for their first long-acting hemophilia program, rFIXFc. This program targets a smaller portion of the $6B global hemophilia market ($1B), but gives us increased confidence overall in the long-acting technology that supports the $5B global Factor 8 market. Based on these results, we are increasing our PO from $157 to $173, driven by higher probability of success for the entire hemophilia program, higher sales estimates for rFIXFc, and adjusting our model for better economics to BIIB."

Biogen Idec closed at $152.83 on Tuesday.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2015BairdDowngradesOutperformNeutral
Jul 2015Morgan StanleyMaintainsOverweight
Jul 2015BernsteinUpgradesMarket PerformOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BIIB)

Get Benzinga's Newsletters